Holen Sie sich die Stockscreener-App
36.66
4.06%
-1.55
Handel nachbörslich:
35.25
-1.41
-3.85%
Schlusskurs vom Vortag:
$38.21
Offen:
$37.59
24-Stunden-Volumen:
3.01M
Relative Volume:
1.45
Marktkapitalisierung:
$2.52B
Einnahmen:
$18.09M
Nettoeinkommen (Verlust:
$-208.87M
KGV:
-10.44
EPS:
-3.5125
Netto-Cashflow:
$-178.15M
1W Leistung:
-8.56%
1M Leistung:
-22.84%
6M Leistung:
+59.25%
1J Leistung:
+144.73%
1-Tages-Spanne:
$35.34
$38.02
1-Wochen-Bereich:
$35.34
$40.86
52-Wochen-Spanne:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Firmenname
Uniqure Nv
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
36.66 | 2.63B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
490.39 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
695.18 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.23 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.86 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.41 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Mizuho | Neutral → Outperform |
| 2026-03-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure Nv Aktie (QURE) Neueste Nachrichten
uniQure earnings in focus as AMT-130 gene therapy BLA looms By Investing.com - Investing.com Australia
Uniqure NV (QURE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Uniqure NV (QURE) Income Statement - TradingKey
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Uniqure NV (QURE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kalehua Capital Management LLC Makes New Investment in uniQure N.V. $QURE - MarketBeat
Orbimed Advisors LLC Has $34.93 Million Holdings in uniQure N.V. $QURE - MarketBeat
Uniqure NV (QURE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
QURE|Uniqure NV|Price:38.250|Chg%:+0.040 - TradingKey
Uniqure NV (QURE) Balance Sheet - TradingKey
QURE|Uniqure NV|Price:38.230|Chg%:-0.740 - TradingKey
Uniqure NV (QURE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Uniqure NV (QURE) Cash Flow - TradingKey
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure N.V. Revenue Breakdown – FWB:UQ1 - TradingView
uniQure (QURE) to Release Earnings on Wednesday - MarketBeat
uniQure N.V. Revenue Breakdown – BIVA:QURE/N - TradingView
Siren L.L.C. Makes New $16.35 Million Investment in uniQure N.V. $QURE - MarketBeat
Aberdeen Group plc Reduces Holdings in uniQure NV - GuruFocus
Uniqure NV (QURE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Earnings Preview: UniQure NV to Report Financial Results Pre-market on July 29 - Moomoo
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Militia Capital Management LLC Purchases New Shares in uniQure N.V. $QURE - MarketBeat
uniQure N.V. to announce Q2 2026 financial results on July 29 - scanx.trade
uniQure to Announce Second Quarter 2026 Financial Results - The Manila Times
uniQure sets July 29 webcast after Q2 financial results - Stock Titan
uniQure N.V. $QURE Shares Sold by Jennison Associates LLC - MarketBeat
JPMorgan Chase & Co. Increases Stake in uniQure NV - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Maintains Target Price $46 - Moomoo
uniQure (QURE) Proxy filing Summary - Quartr
uniQure (NASDAQ:QURE) Shares Pass Above 50 Day Moving AverageTime to Sell? - MarketBeat
Aberdeen Group plc (QURE) discloses 2.85M-share, 4.52% holding in uniQure - Stock Titan
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold? - MSN
What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
uniQure (QURE) Stock Still Looks Expensive Given Its Huntingtons Promise - Yahoo Finance
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - The Globe and Mail
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway - Yahoo Finance
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - GuruFocus
UniQure (QURE) now trades above golden cross: Time to buy? - MSN
JPMorgan discloses 7% uniQure (QURE) stake of 4,866,211 shares - Stock Titan
uniQure's Huntington's prospects brighten after FDA shift - S&P Global
If You Invested $1,000 in Uniqure (QURE) - Stock Titan
uniQure N.V. (NASDAQ:QURE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
The Technical Signals Behind (QURE) That Institutions Follow - Stock Traders Daily
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. $QURE Shares Purchased by Y Intercept Hong Kong Ltd - MarketBeat
UniQure soars as Cantor upgrades on plans to seek gene therapy nod - MSN
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
uniQure (QURE) Status Update Summary - Quartr
Finanzdaten der Uniqure Nv-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure Nv-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Jul 02 '26 |
Sale |
45.16 |
21,082 |
952,051 |
519,227 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
5.59 |
10,000 |
55,900 |
178,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
1.49%
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):